Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-22Clinical Trial Update: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) [Phase 3]
Phase 3 trial update comparing bb2121 to standard regimens in relapsed/refractory multiple myeloma; completed study evaluating efficacy and …
-
CLINICAL_TRIALS trial_result · 2026-06-09Clinical Trial Update: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment [Phase 3]
Phase 3 trial evaluating talquetamab in combination with daratumumab (with or without pomalidomide) versus daratumumab-based regimen in mult…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy [Phase 3]
Phase 3 trial assessing VRd followed by cilta-cel CAR-T versus Rd therapy in newly diagnosed multiple myeloma patients not planned for autol…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Results: Fluoroquinolone Resistance Prevalence Study
A terminated clinical trial study assessing fluoroquinolone resistance prevalence in the context of multiple myeloma; results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Results: Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy [Phase 2]
Phase 2 trial evaluating siltuximab for treating cytokine release syndrome and ICANS associated with CAR-T cell therapy; study completed wit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Natural Killer Cells and Bortezomib to Treat Cancer [Phase 1]
This Phase 1 clinical trial update reports on the combination of natural killer cells and bortezomib for several cancers, and the study has …
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma [Phase 1]
Phase 1 trial update for allogeneic P-BCMA-ALLO1 CAR-T cells in multiple myeloma; the study is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant [Phase 2]
A Phase 2 clinical trial evaluating melphalan with or without siltuximab for multiple myeloma patients undergoing autologous stem cell trans…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma [Phase 1, Phase 2]
A National Cancer Institute trial is evaluating the combination of mirdametinib and sirolimus in relapsed/refractory, RAS-mutated multiple m…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma [Phase 2]
A Phase 2 study evaluating three dosing schedules of daratumumab in participants with smoldering multiple myeloma has completed and posted r…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 dose-escalation trial of teclistamab (Tecvayli), a humanized BCMA-CD3 bispecific antibody, in relapsed or refractory multiple myelom…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Agriculture Health Study
The Agriculture Health Study (NCT00352924) remains active but not recruiting, continuing investigation into pesticide exposures and cancer r…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) [Phase 3]
A Phase 3 trial protocol comparing belantamab mafodotin plus lenalidomide and dexamethasone (BRd) versus daratumumab plus lenalidomide and d…
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) [Phase 2]
Phase 2 MATCH subprotocol T trial update reports testing vismodegib (GDC-0449) in cancers with SMO or PTCH1 mutations; the study is active b…
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating alnuctamab in combination with mezigdomide in relapsed/refractory multiple myeloma has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma [Phase 2]
This Phase 2 clinical trial update evaluates [68Ga]Ga-PentixaFor-PET for initial staging and therapeutic evaluation in multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
A completed clinical trial update detailing a genome expression study in leukemia, multiple myeloma, and lymphomas (Hodgkin and Non-Hodgkin)…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease [Phase 2]
This update describes a Phase 2 trial evaluating a four-drug regimen (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for mult…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: BR101 in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating BR101 in patients with relapsed/refractory multiple myeloma. The study status is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant [Phase 3]
Pfizer is conducting a Phase 3 trial comparing elranatamab to lenalidomide in patients with newly diagnosed multiple myeloma after autologou…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study [NA]
The document reports a completed descriptive pilot study evaluating dermo-cosmetic products to treat skin and nail toxicity in multiple myel…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: A Clinical Study of SHR-9539 in Patients With Multiple Myeloma [Phase 1]
A Phase 1 clinical trial of SHR-9539 in patients with multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 trial evaluating the combination of elotuzumab and lenalidomide after stem cell transplantation in patients with newly diagnosed mul…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating a two-arm regimen for relapsed or refractory multiple myeloma using daratumumab, bortezomib, and dexamethasone foll…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma [Phase 2]
Phase II clinical trial evaluating salvage radiation therapy after BCMA CAR-T therapy in relapsed/refractory multiple myeloma. The study is …